Literature DB >> 21270616

Oncologic results and surgical morbidity of laparoscopic nerve-sparing radical hysterectomy in the treatment of FIGO stage IB cervical cancer: long-term follow-up.

Nae Yoon Park1, Gun Oh Chong, Dae Gy Hong, Young Lae Cho, Il Soo Park, Yoon Soon Lee.   

Abstract

OBJECTIVES: The aim of this study was to evaluate a long-term follow-up data for oncologic results and surgical morbidity of a laparoscopic nerve-sparing radical hysterectomy (NSRH) in the treatment of FIGO stage IB cervical cancer.
METHODS: This was a retrospective study that comprised consecutive 125 patients with cervical cancer stage IB1 (n = 105) and IB2 (n = 20) who underwent a laparoscopic NSRH (Piver type III) by a gynecologic oncologist without selecting patients from January 1999 to December 2007.
RESULTS: In regression analysis, the operating time (R linear = 0.311, P < 0.001) and estimated blood loss (R linear = 0.261, P < 0.001) were decreased, whereas the number of harvested pelvic lymph nodes (R linear = 0.250, P < 0.001) was increased. Seventeen patients (13.6%, 17/125) were found to have pelvic node metastasis. Para-aortic node metastasis had occurred in 2 patients (5.1%, 2/39). There were high urological complications (13/125, 10.4%) related to radical surgery. Forty-one patients (33%) needed transfusions. Positive surgical margins did not exist. Patients were able to self-void at a mean of 10.3 days postoperatively. The return rates to normal voiding function at postoperative 14 and 21 days were 92.0% and 95.2%, respectively. Thirteen patients (IB1 n = 9, IB2 n = 4) experienced a recurrence postoperatively. Six patients (IB1 n = 3, IB2 n = 3) died of recurrent disease. Five-year disease-free survival rates of cervical cancer IB1 and IB2 were 92% and 78%, respectively (P = 0.1772). Five-year overall survival rates of cervical cancer IB1 and IB2 were 96% and 83%, respectively (P = 0.0437).
CONCLUSIONS: A laparoscopic NSRH for FIGO stage IB cervical cancer was comparable to open NSRH in terms of early recovery of bladder function. It did not compromise surgical radicality, but revealed high urological complications, long operating time, and much blood loss, compared with conventional radical hysterectomy. However, these surgical morbidities were corrected with increase in experiences.

Entities:  

Mesh:

Year:  2011        PMID: 21270616     DOI: 10.1097/IGC.0b013e31820731bb

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  Lower urinary tract dysfunction after nerve-sparing radical hysterectomy.

Authors:  Fouad Aoun; Roland van Velthoven
Journal:  Int Urogynecol J       Date:  2014-11-29       Impact factor: 2.894

Review 2.  Lower urinary tract dysfunction in pelvic gynecologic cancer: the role of urodynamics.

Authors:  Fouad Aoun; Alexandre Peltier; Roland van Velthoven
Journal:  Adv Urol       Date:  2014-11-23

3.  Various types of total laparoscopic nerve-sparing radical hysterectomies and their effects on bladder function.

Authors:  Hiroyuki Kanao; Kazuko Fujiwara; Keiko Ebisawa; Tomonori Hada; Yoshiaki Ota; Masaaki Andou
Journal:  J Gynecol Oncol       Date:  2014-07-03       Impact factor: 4.401

4.  Surgical and Oncological Outcome of Total Laparoscopic Radical Hysterectomy versus Radical Abdominal Hysterectomy in Early Cervical Cancer in Singapore.

Authors:  Timothy Yong Kuei Lim; Krystal Koh Miao Lin; Wai Loong Wong; Ieera Madan Aggarwal; Philip Kwai Lam Yam
Journal:  Gynecol Minim Invasive Ther       Date:  2019-04-29

Review 5.  Clinical efficacy and safety of nerve-sparing radical hysterectomy for cervical cancer: a systematic review and meta-analysis.

Authors:  Ying Long; De-Sheng Yao; Xin-Wei Pan; Ting-Yu Ou
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

6.  Robotic-Assisted Radical Hysterectomy Results in Better Surgical Outcomes Compared With the Traditional Laparoscopic Radical Hysterectomy for the Treatment of Cervical Cancer.

Authors:  Ji-Chan Nie; An-Qi Yan; Xi-Shi Liu
Journal:  Int J Gynecol Cancer       Date:  2017-11       Impact factor: 3.437

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.